Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,346 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rituximab maintenance improves outcomes of transformed diffuse large B-cell lymphoma: a retrospective study of 519 cases with de novo diffuse large B-cell lymphoma and 62 cases with concurrent diffuse large B-cell lymphoma and follicular lymphoma.
Uryu H, Mishima Y, Tsuyama N, Yokoyama M, Nishimura N, Fukuta T, Shirouchi Y, Okabe T, Inoue N, Takeuchi K, Terui Y. Uryu H, et al. Among authors: takeuchi k. Leuk Lymphoma. 2021 Sep;62(9):2141-2150. doi: 10.1080/10428194.2021.1901091. Epub 2021 Mar 21. Leuk Lymphoma. 2021. PMID: 33749498
Clinicopathological features of pyothorax-associated lymphoma; a retrospective survey involving 98 patients.
Narimatsu H, Ota Y, Kami M, Takeuchi K, Suzuki R, Matsuo K, Matsumura T, Yuji K, Kishi Y, Hamaki T, Sawada U, Miyata S, Sasaki T, Tobinai K, Kawabata M, Atsuta Y, Tanaka Y, Ueda R, Nakamura S. Narimatsu H, et al. Among authors: takeuchi k. Ann Oncol. 2007 Jan;18(1):122-128. doi: 10.1093/annonc/mdl349. Epub 2006 Oct 16. Ann Oncol. 2007. PMID: 17043091 Free article.
A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study.
Nitta E, Izutsu K, Sato T, Ota Y, Takeuchi K, Kamijo A, Takahashi K, Oshima K, Kanda Y, Chiba S, Motokura T, Kurokawa M. Nitta E, et al. Among authors: takeuchi k. Ann Oncol. 2007 Feb;18(2):364-9. doi: 10.1093/annonc/mdl393. Epub 2006 Nov 1. Ann Oncol. 2007. PMID: 17079695 Free article.
Durable remission after the administration of rituximab for EBV-negative, diffuse large B-cell lymphoma following autologous peripheral blood stem cell transplantation for angioimmunoblastic T-cell lymphoma.
Shinohara A, Asai T, Izutsu K, Ota Y, Takeuchi K, Hangaishi A, Kanda Y, Chiba S, Motokura T, Kurokawa M. Shinohara A, et al. Among authors: takeuchi k. Leuk Lymphoma. 2007 Feb;48(2):418-20. doi: 10.1080/10428190601059761. Leuk Lymphoma. 2007. PMID: 17325908 No abstract available.
CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.
Ennishi D, Takeuchi K, Yokoyama M, Asai H, Mishima Y, Terui Y, Takahashi S, Komatsu H, Ikeda K, Yamaguchi M, Suzuki R, Tanimoto M, Hatake K. Ennishi D, et al. Among authors: takeuchi k. Ann Oncol. 2008 Nov;19(11):1921-6. doi: 10.1093/annonc/mdn392. Epub 2008 Jun 23. Ann Oncol. 2008. PMID: 18573805 Free article.
4,346 results